• Capacity increase will support production of high throughput and large volume gene therapy products

    • March 3, 2020
    • Posted By : admin
    • 0 Comment
    •   14 views

    FUJIFILM Diosynth Biotechnologies U.S.A., Inc. (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and manufacture of their biologics, vaccines and gene therapies has announced that it has commenced the planned capacity expansion of its “Flexible Biomanufacturing Facility” at its College Station, Texas location. The Flexible Biomanufacturing Facility is designed to support late phase and commercial manufacturing of gene therapies and other advanced therapies. The Flexible Biomanufacturing Facility complements the extensive development and early phase manufacturing capabilities provided by the company from the National Centre for Therapeutic Manufacture also located in College Station, Texas.

    The expansion project will include the addition of cell culture and high throughput manufacturing suites. The expanded facility will house multiple 500L and 2000L bioreactors to support the production of gene therapy products that have high production demands.  This $35M USD expansion is part of the previously announced capital investment of approximately 13 billion yen (approx. $120 million USD) in the gene therapy field by FUJIFILM Corporation.

    “The capacity increase to our Flexible Manufacturing Facility will allow us to support the growing demand for commercial-ready, high volume production of gene therapy products, many of which are in development to treat rare diseases, which makes this announcement even more significant, as today we honor rare disease patients on Rare Disease Day,” said Gerry Farrell, chief operating officer, FUJIFILM Diosynth Biotechnologies, Texas.

    “These investments are part of FUJIFILM Corporation’s long term strategy to provide leading, future proofed end-to-end gene therapy solutions, from pre-clinical to commercial launch,” said Martin Meeson, president and chief operating officer, FUJIFILM Diosynth Biotechnologies, U.S.A.

  14 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!